A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combinedwith Intravesical BCG in Participants with BCG-Unresponsive, High-Risk,Non-Muscle Invasive BladderCancer

Project: Research project

Project Details

Description

A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined with Intravesical BCG in Participants with BCG-Unresponsive, High-Risk,Non-Muscle Invasive Bladder Cancer
StatusActive
Effective start/end date7/5/187/30/23

Funding

  • BRISTOL-MYERS SQUIBB COMPANY

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.